Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

22nd Century Group Inc. (XXII)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 322,492
  • Shares Outstanding, K 123,560
  • Annual Sales, $ 12,280 K
  • Annual Income, $ -11,580 K
  • 36-Month Beta 2.97
  • Price/Sales 26.26
  • Price/Cash Flow N/A
  • Price/Book 11.51
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.13
  • Most Recent Earnings -0.03 on 11/09/17
  • Next Earnings Date 11/14/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-2111 Cigarettes

    Tobacco

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.11 +25.59%
on 11/16/17
2.92 -9.40%
on 12/11/17
+0.52 (+24.41%)
since 11/15/17
3-Month
1.95 +35.90%
on 11/03/17
3.50 -24.29%
on 10/06/17
-0.56 (-17.45%)
since 09/15/17
52-Week
0.81 +227.16%
on 01/12/17
3.50 -24.29%
on 10/06/17
+1.67 (+170.41%)
since 12/15/16

Most Recent Stories

More News
Legal Cannabis Sales Grow Globally

According to a report published by Grand View Research, the global medical cannabis market is expected to reach USD 55.8 billion by 2025. Rising awareness of various medical applications in cannabis is...

KSHB : 2.9000 (-0.68%)
CRBP : 7.15 (-2.05%)
XXII : 2.65 (+1.53%)
ZYNE : 11.47 (+0.44%)
DJACF : 1.0100 (-0.98%)
Technical Perspectives on Protalix BioTherapeutics, 22nd Century, CorMedix, and iBio

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on PLX, XXII, CRMD, and IBIO which is a click away at www.wallstequities.com/registration....

XXII : 2.65 (+1.53%)
CRMD : 0.57 (+2.68%)
IBIO : 0.15 (unch)
PLX : 0.61 (-1.45%)
The Legal Cannabis Market is Expected to Grow Globally

According to a report by Forbes, Brightfield Group, a cannabis market research firm, indicates that the international market for cannabis is projected to hit $31.4 billion by 2021. Bethany Gomez, Director...

CBDS : 4.7800 (+0.21%)
CANN : 3.5000 (-0.28%)
CBWTF : 0.6750 (-1.46%)
CVSI : 0.3575 (+11.72%)
XXII : 2.65 (+1.53%)
KWFLF : 0.7793 (-1.19%)
22nd Century Hires Former BAT Head of Plant Biotechnology

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and hemp/cannabis research, announced today the hiring of Juan Sanchez ...

BTI : 65.86 (+0.12%)
XXII : 2.65 (+1.53%)
22nd Century Ships 2.4 Million SPECTRUM(R) Cigarettes for the National Institute on Drug Abuse

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and hemp/cannabis research, announced today that the Company shipped 2.4 ...

XXII : 2.65 (+1.53%)
Cannabis Sales Expected to Grow Due to Medical Benefits

According to Hexa Research, the U.S. medical cannabis market size was valued at USD $5.44 Billion in 2016 and is expected to hit USD $19.48 billion by 2024. The industry is expected to witness rapid growth...

NUVPD : 0.1543 (-9.24%)
EMHTF : 3.7984 (-2.17%)
CRBP : 7.15 (-2.05%)
NUVPF : 0.2503 (-10.61%)
XXII : 2.65 (+1.53%)
ZYNE : 11.47 (+0.44%)
Medical Cannabis Data Shows Strong Sales and Growth

According to a research published by Hexa Research, the U.S. medical cannabis market size was valued at USD 5.44 billion in 2016, and is expected to be valued $19.48 billion by 2024. The medical cannabis...

CBDS : 4.7800 (+0.21%)
CARA : 12.71 (+0.71%)
VRTHF : 0.4562 (-5.74%)
GWPH : 130.21 (-0.47%)
XXII : 2.65 (+1.53%)
Anticipating FDA's "Reduced Nicotine Mandate," 22nd Century Will Discontinue U.S. Sales of RED SUN Brand

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and hemp/cannabis research, announced today that, in preparation for the ...

XXII : 2.65 (+1.53%)
Become a “Marijuana Millionaire” — Without Risking a Dime in the Market

This post Become a “Marijuana Millionaire” — Without Risking a Dime in the Market appeared first on Daily Reckoning . Investors are making a fortune in the marijuana industry... but cannabis...

CVSI : 0.3575 (+11.72%)
XXII : 2.65 (+1.53%)
MYHI : 0.0800 (-3.38%)
22nd Century Group Files 2017 Third Quarter Report and Announces Conference Call to Provide Business Update

--Leading regulatory expert, Dr. James Swauger, will lead and oversee the re-submission to the FDA of the Company's MRTP application for BRAND A Very Low Nicotine Content cigarettes.

XXII : 2.65 (+1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products...

See More

Key Turning Points

2nd Resistance Point 2.76
1st Resistance Point 2.71
Last Price 2.65
1st Support Level 2.60
2nd Support Level 2.54

See More

52-Week High 3.50
Last Price 2.65
Fibonacci 61.8% 2.47
Fibonacci 50% 2.15
Fibonacci 38.2% 1.84
52-Week Low 0.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.